Tirzepatide
What does "GIP/GLP-1 Dual Receptor Agonist" mean?
This peptide activates TWO different hormone receptors simultaneously. GIP and GLP-1 are both "incretin" hormones - chemicals your gut releases after eating to help manage blood sugar and appetite.
Explained Simply
Your body has two different "I'm full" buttons. Most medicines only press one button. Tirzepatide presses BOTH buttons at the same time, which can make the "full" feeling even stronger.
How It Works
Tirzepatide activates both GIP and GLP-1 receptors simultaneously. GIP receptor activation enhances insulin secretion and may improve fat cell function.
Research by Sex
Effects in Men
- •Clinical trials show robust efficacy across male participants
- •Research indicates significant reductions in visceral adipose tissue
- •Studies suggest improvements in lipid profiles
Effects in Women
- •Women show comparable or enhanced response in clinical studies
- •Research indicates potential benefits across different hormonal phases
- •Studies show significant improvements in metabolic markers in post-menopausal women
Key Terms Explained
GIP
Glucose-dependent Insulinotropic Polypeptide, an incretin hormone that enhances insulin release
Dual Agonist
A compound that activates two different receptor types simultaneously
Research Areas
- •Dual incretin receptor activation mechanisms
- •Comparative efficacy vs single receptor agonists
- •Weight management and body composition
Published Studies
Laboratory Protocols
Storage
Store lyophilized peptide at -20°C. Reconstituted solution should be stored at 2-8°C.
Reconstitution
Reconstitute with bacteriostatic water. Allow vial to reach room temperature before reconstitution.
Quick Facts
Category
GIP/GLP-1 Dual Receptor Agonist
Molecular Weight
4813.45 g/mol
Half-Life
~5 days
Amino Acid Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(palmitoyl-γGlu-AEEA-AEEA)-Ile-Ala-Gln-Ala-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
Grokipedia
Quick Reference
View detailed research data including key facts, mechanism of action, and safety profile.
Disclaimer: This information is provided for educational purposes only. These products are intended for laboratory research use only. Not for human consumption.
Grokipedia
Quick Reference
Tirzepatide
Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist with biased agonism favoring GIP receptor activation. It activates two incretin hormone pathways simultaneously.
Key Facts
- •Dual GIP/GLP-1 agonist
- •Molecular weight: 4813.45 g/mol
- •Half-life: approximately 5 days
- •Biased toward GIP activation
- •Once-weekly dosing
Mechanism of Action
Simultaneously activates GIP and GLP-1 receptors. GIP enhances insulin secretion and may improve fat cell function. GLP-1 reduces appetite and improves glucose handling. Combined action may exceed single-agonist effects.
Research Applications
- Dual incretin pathway research
- Comparative efficacy studies
- Metabolic function research
- Body composition studies
Safety Profile
FDA-approved for certain indications. GI symptoms most common. Similar precautions to GLP-1 class. Research use requires appropriate oversight.
Disclaimer: This information is for educational and research purposes only. Products are intended for laboratory research use only. Not for human consumption.